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Abstract 
Purpose: Carbapenem resistant K. pneumoniae (CRKP) has aroused widespread attention owing to its very limited 
therapeutic options, and this strain has increased rapidly in recent years. Although it is accepted that drug resistance 
is associated with increased mortality in general, but some other studies found no such relationship. To estimate mor-
tality of patients infected with CRKP in general and analyze factors for mortality of this infection, thus, we conducted 
this systematic review and meta-analysis.
Methods: A systematic literature review of relevant studies published until December 2015 was conducted. We 
selected and assessed articles reporting mortality of patients infected with CRKP.
Results: Pooled mortality was 42.14% among 2462 patients infected with CRKP versus 21.16% in those infected with 
carbapenem-susceptible K. pneumoniae (CSKP). The mortality of patients with bloodstream infection (BSI) or urinary 
tract infection was 54.30 and 13.52%, respectively, and 48.9 and 43.13% in patients admitted to the intensive care unit 
(ICU) or who underwent solid organ transplantation (SOT). Mortality was 47.66% in patients infected with K. pneu-
moniae carbapenemase-producing K. pneumoniae and 46.71% in those infected with VIM-producing K. pneumoniae. 
Geographically, mortality reported in studies from North America, South America, Europe, and Asia was 33.24, 46.71, 
50.06, and 44.82%, respectively.
Conclusions: Our study suggests that patients infected with CRKP have higher mortality than those infected with 
CSKP, especially in association with BSI, ICU admission, or SOT. We also considered that patients’ survival has a close 
relationship with their physical condition. Our results imply that attention should be paid to CRKP infection, and that 
strict infection control measures and new antibiotics are required to protect against CRKP infection.
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Background
It is well known that Klebsiella pneumoniae is ubiquitous 
in nature, one of the most relevant opportunistic patho-
gens, and causes various human infections such as blood-
stream infection (BSI), urinary tract infection (UTI), 
surgical-site infection, and pneumonia [1–3]. Resist-
ance can develop in K. pneumoniae isolates, notably 
producing extended-spectrum β-lactamases (ESBLs). 
ESBL-producing strains of K. pneumoniae are currently 
found throughout the world and have caused numerous 
outbreaks of infection [4, 5]. Carbapenems represent the 
first-line therapy for severe infection by ESBL-produc-
ing K. pneumoniae [6]. However, since Yigit et  al. [7, 8] 
reported the first K. pneumoniae carbapenem (KPC)-
producing K. pneumoniae isolate in North Carolina in 
1996, carbapenem-resistant strains have increased rap-
idly, rising from 1.6 to 10.4% associated with central line 
blood-stream infections between 2001 and 2011 in the 
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United States, and have aroused widespread attention, 
presenting a challenge because the antimicrobial treat-
ment options remain very restricted [7, 9].
Carbapenem-resistant K. pneumoniae (CRKP) deacti-
vates the carbapenems through two main mechanisms: 
(1) acquisition of carbapenemase genes that encode for 
enzymes capable of hydrolyzing carbapenems—the three 
most important carbapenemase types being KPC-type 
enzymes, metallo-β-lactamases (VIM, IMP, NDM), and 
OXA-48 type enzymes; and (2) reduction in the accumu-
lation of antibiotics by a quantitative and/or qualitative 
deficiency of porin expression in combination with over-
expression of β-lactamases that possess weak affinity for 
carbapenems [10].
Most researchers reported higher mortality rates 
among persons infected with CRKP isolates [11–30] 
while others reported contrary results [31, 32]. In recent 
years, many studies from single medical centers or indi-
vidual countries have reported mortality rates in patients 
infected with CRKP, but until now there has been no 
systematic review focusing on mortality resulting from 
carbapenem-resistant infections in general. Although in a 
recent meta-analysis Falagas et al. [33] reported a higher 
all-cause mortality among patients infected with carbap-
enem-resistant Enterobacteriaceae than in those with 
carbapenem-susceptible infections, but their research 
included only nine studies. Considering this scenario, 
we conducted a systematic review and meta-analysis to 
estimate the mortality of patients infected with CRKP, 
and analyzed mortality resulting from multiple infection 
types and patients conditions.
Methods
Search strategy
Two independent examiners (LF.X. and XX.S.) searched 
entries in the PubMed and EMBASE databases from their 
inception until December 22, 2015 to identify potentially 
relevant studies. The search terms included “Klebsiella 
pneumoniae” AND resistance AND (“carbapenem” OR 
“imipenem” OR “meropenem” OR “ertapenem”). The lan-
guage was restricted to English.
Inclusion and exclusion criteria
Studies were considered in accordance with inclusion 
criteria if articles reported mortality of patients infected 
with CRKP. Research that focused on children, did not 
differentiate mortality between infection and coloniza-
tion, did not define the strains that were carbapenem 
resistant, and did not present the exact death toll were 
excluded. In this analysis, carbapenem resistance was 
defined as resistance to carbapenems such as imipenem, 
meropenem, and ertapenem, irrespective of susceptibility 
to other antibiotics.
Assessment of study quality
The articles were assessed for quality of the cohort or 
case–control studies included in the systematic analysis 
according to the Newcastle-Ottawa scale (NOS) score 
[34], ranging from 0 to 9. Studies with a NOS score of 5 
or greater were included in this analysis.
Data extraction
Two independent investigators (LF.X. and XX.S.) 
extracted information from eligible articles. Divergences 
were solved by discussion and consultation of the rel-
evant literature. The information extracted from original 
publications included title, first author, year of publica-
tion and experiment, type of study, sample size, char-
acteristics of the study population (mean age, sex, type 
of infection, mean severity of underlying disease), and 
crude mortality rates in patients infected with CRKP and 
carbapenem-susceptible K. pneumoniae (CSKP). If arti-
cles reported mortality from both infection and coloniza-
tion, we extracted information only regarding infections.
Statistical analysis
We calculated the pooled odds ratio (OR) and 95% con-
fidence interval (CI) by comparing crude mortality in 
patients with CRKP with that in patients with CSKP. 
Between-study heterogeneity was assessed by the χ2 test 
(p  <  0.10 was selected to indicate the presence of het-
erogeneity, in which case a random-effects model was 
adopted; otherwise a fixed-effects model was applied) 
and I2 test (to assess the degree of heterogeneity) [35, 36]. 
We then calculated pooled rates of mortality in patients 
infected with CRKP, and stratified analyses with respect 
to geographic location, infection types, carbapenemase 
types, and patients conditions performed. Freeman–
Tukey arcsine transformations were used to stabilize the 
variances, and after the meta-analysis we transformed 
the summary estimates and the CI boundaries back to 
proportions using the sine function [37]. We used Stata 
version 12.0 software for all statistical calculations.
Results
Results of the systematic literature search
We identified and screened 3168 articles. After exclusion 
by title and abstract, the remaining 87 articles were sub-
jected to full-text assessment for eligibility. Among these 
articles, 12 were duplicates, seven did not differentiate 
between infection- and colonization-related mortality, 
and six did not report valid data. Ultimately, 62 studies 
were analyzed based on the inclusion and exclusion cri-
teria (Fig. 1).
The basic characteristics of these 62 studies are sum-
marized in Table  1 [11–32, 38–77]. These articles were 
published from 1999 to 2015 and the sample size varied 
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across studies, ranging from 7 to 1022. The total number 
of patients in this systematic review was 4701, of whom 
2462 had CRKP infection and the remainder CSKP infec-
tion. Among these patients, the reported death was 1018 
among the CRKP patients and 398 among the CSKP 
patients. In the pooled analysis, the overall mortality 
was 42.14% (95% CI 37.06–47.31) in patients infected 
with CRKP and 21.16% (95% CI 16.07–26.79) in CSKP 
patients (Table 2). 
Comparison of mortality in CRKP and CSKP patients
Among the included articles, 22 compared mortality 
between patients infected with CRKP and CSKP. The 
summary estimate of these studies from the random-
effects model suggested that patients with CRKP had a 
significantly higher mortality than those with CSKP in 
the univariate analysis (pooled crude OR 2.80; 95% CI 
2.15–3.65) with a moderate heterogeneity I2 of 33.9% 
(p = 0.031) (Fig. 2).
Mortality in multiple patient conditions
As shown in Table 2, 722 patients had BSI and 284 had 
UTI, 479 were in an intensive care unit (ICU), and 362 
underwent solid organ transplantation (SOT). In the 
pooled analysis, the mortality was 54.30% (95% CI 
47.51–61.02), 13.52% (95% CI 7.50–20.92), 48.9% (95% CI 
44.47–53.46), and 43.13% (95% CI 32.40–54.16) in BSI, 
UTI, ICU-admission, and SOT patients, respectively.
Mortality in multiple carbapenemase types
In this subgroup analysis, we mainly analyzed the mortal-
ity of patients infected with KPC-producing K. pneumo-
niae and VIM-producing K. pneumoniae. In the articles 
included, 302 patients were infected with KPC-producing 
K. pneumoniae and 73 were infected with VIM-produc-
ing K. pneumoniae. The mortality among these two types 
of carbapenemases was 47.66% (95% CI 38.61–56.79) and 
46.71% (95% CI 35.81–57.73), respectively (Table 2).
Mortality in different geographic locations
Twenty-three studies were carried out in North America, 
eight in South America, twenty-one in Europe, and ten 
in Asia. The rate of mortality was 33.24% (95% CI 25.08–
42.00) of 980 patients in North America, 46.71% (95% 
CI 39.83–53.66) of 191 in South America, 50.06% (95% 
CI 41.45–58.62) of 860 in Europe, and 44.82% (95% CI 
37.83–51.91) of 431 in Asia (Table 2).
Discussion
ESBL-producing K. pneumoniae as an opportunistic 
pathogen is becoming more challenging to treat because 
of the emergence of carbapenem resistance, and has a 
significant influence on patient mortality. The primary 
result of this analysis was the pooled crude mortality of 
42.14% among patients with CRKP, which is intimately 
connected with patients’ health and physical status.
Although it is accepted that drug resistance is associ-
ated with increased mortality because patients tend to 
receive inappropriate empiric therapy in general [4, 78], 
other studies have found no such relationship. Bhav-
nani et al. [79] reported that clinical success was similar 
between patients with ESBL and those with non-ESBL-
producing K. pneumoniae, and ESBL production alone 
did not appear to be an independent risk factor for treat-
ment failure. Kim et  al. [80] also found that ESBL pro-
duction was not significantly associated with death. In 
addition, García-Sureda et  al. [81] reported that CRKP 
isolates are less virulent and fit than CSKP isolates in an 
antibiotic-free environment. We conducted this system-
atic review and meta-analysis to estimate the mortality 
of patients infected with CRKP in general and to study 
the factors related to mortality resulting from this infec-
tion. We found that patients infected with CRKP had 
significantly higher mortality in comparison with CSKP 
(crude OR 2.80). To identify risk factors associated with 
the higher mortality of CRKP infections, we conducted 
a stratified analysis of patient condition, carbapenemase 
types, and study location.
Based on multiple patient conditions, our analysis con-
firmed that patients with CRKP in association with BSI, 
ICU admission, or SOT have a higher mortality than the 
pooled mortality, although UTI patients have a lower 
mortality than the pooled overall mortality, even lower 
than that of CSKP patients. From this result, we assumed 
that patient survival has a close relationship with patients’ 
underlying illness and comorbidities. Mouloudi et al. [26] 
reported that BSI, ICU admission, and recent receipt of a 
Fig. 1 Flow diagram of included studies
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Table 2 Mortality of patients based on patient condition, carbapenemases type, study region
CRKP Carbapenem-resistant K. pneumoniae, CSKP carbapenem-susceptible K. pneumonia
Subgroup Number of studies Sample size Mortality Rate %(95% CI) Statistical model
Pooled mortality P < 0.001
 CRKP 62 2462 42.14 (37.06–47.31) Random
 CSKP 22 2239 21.12 (16.07–26.79) Random
Patient conditions P < 0.001
 Bloodstream infections 20 722 54.30 (47.51–61.02) Random
 Urinary tract infections 8 284 13.52 (7.50–20.92) Random
 Intensive care unit 12 479 53.90 (39.44–68.00) Random
 Solid organ transplantation 15 362 43.13 (32.40–54.16) Random
Carbapenemases type P = 0.645
 KPC-producing Klebsiella pneumoniae 13 302 47.66 (38.61–49.51) Random
 VIM-producing Klebsiella pneumoniae 5 73 46.71 (35.81–57.73) Random
Region P = 0.062
 North America 23 980 33.24 (25.08–42.00) Random
 South America 8 191 46.71 (39.83–53.66) Fixed
 Europe 21 860 50.06 (41.45–58.62) Random
 Asia 10 431 44.82 (37.83–51.91) Random
Fig. 2 Crude odds ratio (OR) for the association between carbapenem resistance and mortality of patients with K. pneumoniae infection
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SOT were associated with ICU and in-hospital mortality 
in patients infected with CRKP. In addition, patients who 
had undergone organ transplantation or ICU admission 
were always subjected to surgical procedures, prolonged 
ICU stay, preexisting immunosuppression, and the use 
of invasive devices, which contributed to patients’ poor 
physical condition and resultant higher mortality. In con-
trast, Daikos et al. suggested that UTI is a relatively mild 
infection that has only a slight influence on the general 
condition of patients, and carries a low mortality in gen-
eral [25]. It has been shown that factors such as under-
lying illness and comorbidities have a more important 
influence on mortality than appropriate empiric treat-
ment with multidrug-resistant Gram-negative bacte-
ria [82]. Although the underlying patient’s condition is 
important for the outcome of such patients, meanwhile 
a timely effective treatment can also help to improve the 
survival rate. Patients in a poor state of health with CRKP 
were subjected to pathogens longer compared to CSKP 
infection due to lack of an effective therapy, ultimately, 
led to a higher mortality.
In the present analysis, patients infected with KPC-
producing K. pneumoniae have a higher mortality than 
pooled overall mortality (47.66 vs 42.14%). This result 
may contribute to KPC-producing K. pneumoniae hav-
ing stronger invasiveness, and the KPC-encoding blaKPC 
always carry other drug-resistant genes, leading to a 
pronounced drug resistant [83]. Previous studies have 
demonstrated K. pneumoniae-encoding blaKPC to be an 
independent risk factor in patient mortality [26, 27]. In 
addition, KPC-producing K. pneumoniae is considered a 
successful pathogen because of its ability to persist and 
spread, causing nosocomial outbreaks. Bratu et  al. [84] 
reported that KPC-producing K. pneumoniae isolates 
are resistant to not only all β-lactam antimicrobials but 
also frequently other classes of antimicrobials, such as 
aminoglycosides and fluoroquinolones. In this system-
atic review, the patients from North America have lower 
mortality in comparison with the other three locations. 
This phenomenon may be attributed to a higher level of 
medical care and different treatment methods in North 
America, such as combination antibiotics, treatment with 
polymyxins and tigecycline, and adjunctive procedures 
(e.g., catheter removal, drainage, or debridement). There 
is evidence that tigecycline and polymyxins have activity 
against many CRKP isolates in vitro, and there have been 
cases reported of successful treatment of CRKP infection 
with polymyxins and tigecycline [85–87]. Patel et al. [30] 
also reported that removal of the focus of infection (i.e., 
debridement) was independently associated with patient 
survival.
There are several limitations to this analysis. First, 
as the included studies reported only unadjusted data 
on mortality, we analyzed only crude mortality among 
patients with CRKP. Second, most studies may have 
lacked power in differentiating death caused by CRKP 
from any other factors, and it is difficult to draw defini-
tive conclusions from current evidence because of the 
residual confounding factors and small sample sizes in 
many studies. Third, some studies included in our meta-
analysis did not define a cutoff value to judge the sus-
ceptibility of K. pneumoniae to carbapenems, and when 
defined the cutoff value varied among studies owing to 
different reference criteria. Thus, there exists the poten-
tial for heterogeneity. Fourth, most studies were retro-
spective in nature and thus susceptible to selection bias. 
Last, we selected only English-language articles, thus lim-
iting the scope of our analysis.
Conclusions
Our study suggests that patients infected with CRKP 
have a higher mortality than those infected with CSKP, 
especially patients with BSI, ICU admission, or SOT 
intervention. We suggest that the survival of patients has 
a close relationship with their physical condition. Thus, 
our results imply that attention should be paid to CRKP 
infection in patients in a poor state of health, and that 
strict infection control measures and new antibiotics are 
required to protect against CRKP infection.
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